New Immunooncology Drug from Incyte Raises Immense Interest at ASCO

Excitement at ASCO 2014 on Incyte's new immunoonoclogy drug candidate, INCB024360 ('360),in melanoma, despite a small 'n'.

We just got our first look at the clinical activity of


immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with


Yervoy in melanoma patients

Incyte'sBristol-Myers Squibb's

Four immunotherapy-naive melanoma patients dosed with 50 mg of '360 plus Yervoy yielded 1 complete response and 1 partial response for an overall response

of 50%. A third patient reported stable disease so the disease control rate was 75%. The



rateIncyte press release and poster can be found here

Source: The Street

Related Videos
Related Content
© 2023 MJH Life Sciences
All rights reserved.